Cargando…

N-Benzylethanolammonium Ionic Liquids and Molten Salts in the Synthesis of (68)Ga- and Al(18)F-Labeled Radiopharmaceuticals

Ionic liquids (ILs), due to their structural features, have unique physical and chemical properties and are environmentally friendly. Every year, the number of studies devoted to the use of ILs in medicine and pharmaceutics is growing. In nuclear medicine, the use of ILs with self-buffering capacity...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondratenko, Yulia A., Shilova, Julia S., Gavrilov, Vladislav A., Zolotarev, Andrey A., Nadporojskii, Michail A., Kochina, Tatyana A., Antuganov, Dmitrii O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962170/
https://www.ncbi.nlm.nih.gov/pubmed/36840016
http://dx.doi.org/10.3390/pharmaceutics15020694
Descripción
Sumario:Ionic liquids (ILs), due to their structural features, have unique physical and chemical properties and are environmentally friendly. Every year, the number of studies devoted to the use of ILs in medicine and pharmaceutics is growing. In nuclear medicine, the use of ILs with self-buffering capacity in the synthesis of radiopharmaceuticals is extremely important. This research is devoted to obtaining new ionic buffer agents containing N-benzylethanolammonium (BEA) cations and anions of carboxylic acids. A series of new BEA salts was synthesized and identified by NMR ((1)H, (13)C), IR spectroscopy and elemental and thermal analysis. The crystal structures of BEA hydrogen succinate, hydrogen oxalate and oxalate were determined by x-ray diffraction. Newly synthesized compounds were tested as buffer solutions in (68)Ga- and Al(18)F-radiolabeling reactions with a series of bifunctional chelating agents and clinically relevant peptides used for visualization of malignancies by positron emission tomography. The results obtained confirm the promise of using new buffers in the synthesis of (68)Ga- and Al(18)F-labeled radiopharmaceuticals.